I'm LongbridgeAI. Here is the key information I extracted- The evaluation is driven by an estimated 85 percent probability of success for the NATiV3 trial of lanifibranor in treating MASH.…
H.C. Wainwright analyst Ananda Ghosh has maintained their bullish stance on IVA stock, giving a Buy rating on November 1.
Ananda Ghosh’s rating is based on several factors, including an expert hepatologist’s view that lanifibranor could stand out if it produces a roughly 19–20-point placebo-adjusted fibrosis improvement in MASH. Ghosh expects NATiV3 to meet its primary endpoint, assigning about an 85% success probability and 78% for success on both the composite and fibrosis measures. Those expectations are supported by lanifibranor’s strong Phase 2 results and the larger Phase 3 study’s ability to achieve significance with a smaller effect.
He also sees a commercial role for an oral, insulin-sensitizing antifibrotic used alongside incretin therapies, with Rezdiffra the more relevant competitor; differentiation could support adoption among F3 patients and injection-averse or diabetic patients. Scenario analysis indicates substantial upside, while the shares’ roughly $0.84 billion valuation creates an asymmetric risk/reward profile despite safety, placebo-response, payer, and competitive risks. The price target remains unchanged at $14, reinforcing the Buy recommendation ahead of the readout.
In another report released on November 1, UBS also maintained a Buy rating on the stock with a $12.00 price target.
